Janice P Dutcher

6PUBLICATIONS
13CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Psycholinguistics (incl. speech production and comprehension)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.

Leonard J Appleman, Se Eun Kim, Wayne B Harris

|Apr 09, 2021
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).

Wenxin Xu, Mäneka Puligandla, Brian Halbert

|Feb 05, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.

Joseph I Clark, Brendan Curti, Elizabeth J Davis

|Mar 29, 2019
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry.

M Fishman, J P Dutcher, J I Clark

|Aug 15, 2018
Interleukin-2 Can Cure Kidney Cancer.

Janice P Dutcher, Peter H Wiernik

|Jul 20, 2018
"Pseudoprogression": more than semantics.

Janice P Dutcher

Pageof 1

Frequent Collaborators

1 joint publications

Peter H Wiernik

1 joint publications

Wenxin Xu

1 joint publications

Brian Halbert

1 joint publications

Leonard J Appleman